Immunization with the B oligomer of pertussis toxin protected neonatal mice from a lethal respiratory challenge with Bordetella pertussis. All mice immunized with 8 ,ug of B oligomer survived aerosol challenge and had peripheral leukocyte counts and weight gains similar to those of mice immunized with pertussis toxoid before challenge and to those of control mice that were not challenged. Unprotected mice challenged with an aerosol of B. pertussis had an increase in peripheral leukocyte count, failed to gain weight, and died within 21 days of challenge. Protection appeared to be dose dependent, since a dose of 1 ,ug of B oligomer per mouse prevented death in 100% of the mice challenged with B. pertussis, whereas 0.4 ,ug of B oligomer protected 50% of the challenged mice. Mice immunized with the B oligomer had increases in immunoglobulin G (IgG) anti-B oligomer in sera and in IgG and IgA anti-B oligomer in bronchoalveolar lavage fluids 1 to 3 weeks after respiratory challenge. Specific anti-B oligomer antibodies could not be detected in unimmunized, infected mice at the same time after challenge. Intravenous administration of the monoclonal antibody 170C4, which binds to the S3 subunit of the B oligomer, protected neonatal mice from B. pertussis respiratory challenge, while administration of an IgGl anti-tetanus toxin monoclonal antibody, 18
Bordetella pertussis, the etiologic agent of pertussis (whooping cough), is a gram-negative rod that was first isolated by Bordet and Gengou in 1906 (4) . Pertussis, which may be characterized by episodes of paroxysmal coughing, can be fatal, especially in unimmunized infants (7) . Mass immunization of children in the United States with an inactivated whole-cell pertussis vaccine has resulted in a decreased incidence of disease (6) . However, the association of common local and systemic reactions, such as pain and swelling at the injection site and fever, with use of the whole-cell pertussis vaccine (9) has led to an effort to develop an effective acellular vaccine against B. pertussis with fewer side effects. This has led to the purification and analysis of components of B. pertussis as protective antigens. Of these, the most widely studied has been pertussis toxin.
Biological activities mediated by pertussis toxin include leukocytosis, inhibition of leukocyte chemotaxis, histamine sensitization, and insulin secretion (18) . Pertussis toxin is an ADP-ribosyltransferase, with the classic A-B composition of many bacterial toxins (27) . The A promoter (also known as Si) ADP-ribosylates a guanine nucleotide binding protein of eucaryotic cells, thus interfering with signal transduction (12) . The B oligomer, composed of five subunits (S2, S3, S5, and two molecules of S4), is responsible for the binding of the toxin to eucaryotic membranes (28) .
The B oligomer of pertussis toxin dissociates from the A promoter in the presence of ATP and detergent and can be purified by ion-exchange chromatography (2, 5) . Arciniega and coworkers have demonstrated that purified B oligomer elicits antibodies in mice which can neutralize pertussis toxin-induced clustering of Chinese hamster ovary cells in * Corresponding author.
vitro and that mice immunized with B oligomer are refractory to pertussis toxin-induced leukocytosis in vivo (2) . Because certain parameters of pertussis in humans, such as leukocytosis, specific attachment of bacteria to the ciliated epithelium of the respiratory tract, and an increased severity of disease in the neonate, are also observed in mice challenged with an aerosol of B. pertussis (22, 23) (8) . Pertussis holotoxin was inactivated with 0.15% glutaraldehyde as previously described (2) .
The B oligomer of pertussis toxin was purified by incubating holotoxin in ATP and detergent, followed by ion-exchange chromatography, as previously described (2 Analysis of respiratory and serum immunoglobulin. Mice anesthetized with 2,2,2-tribromoethanol (Aldrich Chemical Co., Milwaukee, Wis.) were bled from the brachial arteries, and their tracheas were cannulated with a piece of PE-S0 polyethylene tubing (Clay Adams, Parsippany, N.J.). Sterile phosphate-buffered saline (0.3 ml) was gently instilled into the lungs and withdrawn three times. The bronchoalveolar lavage fluid was centrifuged, and the supernatant was removed and frozen at -20°C prior to analysis.
Sera and bronchoalveolar lavage fluids were analyzed for specific antibodies by an enzyme-linked immunosorbent assay (17 (Fig. 1) . In contrast, mice immunized with 8 jig of tetanus toxoid, as a negative control, exhibited a pronounced increase in peripheral WBC count and failed to gain weight, and all of those mice died within 21 days after respiratory challenge (Fig. 1) .
Immunization with B oligomer protected neonates in a dose-dependent manner. Figure 2 shows leukocytosis evaluated on day 16 (Fig. 2) . Induction of serum and respiratory antibody. No detectable antibody to either B oligomer or pertussis holotoxin was observed at the time of aerosol challenge in the sera or bronchoalveolar lavage fluids of neonatal mice immunized with 8 ,ug of B oligomer (Table 1) . However, increased titers of specific antibody to B oligomer were detected in the sera and bronchoalveolar lavage fluids of immunized mice 1, 2, and 3 weeks after aerosol infection. IgG anti-B oligomer was detected in the sera, while both IgG and IgA antibodies to B oligomer were detected in bronchoalveolar lavage fluids of immunized mice after challenge. Specific antibodies to B oligomer could not be detected in the sera or bronchoalveolar lavage fluids of unimmunized adult mice 1 or 2 weeks after aerosol challenge (Table 1) . Adult mice were used as the controls in the latter experiment, as unimmunized neonates die within 14 to 21 days after aerosol challenge.
Protection mediated by passive antibody. The mouse monoclonal antibody 170C4 is an IgGl antibody that binds to the S3 subunit of the pertussis toxin B oligomer (30 magnitude until the mice died 2 to 3 weeks after B. pertussis aerosol challenge (Fig. 1) .
B oligomer appeared to protect in a dose-dependent fashion, as only 41% of the animals receiving 0. (2) ; this antiserum was also demonstrated to inhibit the pertussis toxin-induced clustering of CHO cells in vitro. Active immunization of adult mice with purified B oligomer also prevented pertussis toxin-induced leukocytosis in vivo. These experiments suggest that active immunization with B oligomer elicits neutralizing antibodies specific for determinants on the B oligomer that do not cross-react with S1.
Passive administration of 170C4, an IgGl monoclonal antibody specific for the S3 subunit of the B oligomer, was sufficient to completely protect young mice from lethal B. pertussis challenge. 170C4 neutralizes the pertussis holotoxin-induced clustering of CHO cells in vitro (Table 2) and has been demonstrated to inhibit pertussis toxin-induced hemagglutination (30) . We have previously shown that IgGl monoclonal antibodies injected intravenously 24 h before challenge can be detected in the lungs of mice at the time of aerosol challenge (25) . Elicitation of pertussis toxin-neutralizing antibodies in the lungs as well as in the systemic circulation may therefore be one mechanism of protection (20) . This monoclonal antibody also inhibited the pertussis toxin-induced clustering of CHO cells, leukocytosis, and hemagglutination. These protection data indicate that antibodies to B oligomer that can neutralize pertussis toxin are sufficient to protect neonatal mice against lethal respiratory B. pertussis infection.
Monoclonal antibodies to Si, the ADP-ribosyltransferase, have previously been shown to neutralize pertussis toxininduced CHO cell aggregation in vitro (14, 21, 24) and leukocytosis in vivo (1, 19, 24) as well as to protect neonatal mice from lethal B. pertussis aerosol challenge. These anti-S1 monoclonal antibodies appear to react with a single immunodominant conformational epitope of Si that is necessary for the enzymatic activity of the molecule as well as for eliciting neutralizing antibody (3). We show here that a neutralizing antibody to the S3 subunit of B oligomer that does not cross-react with Si is sufficient to protect neonatal mice against lethal B. pertussis aerosol challenge. This monoclonal anti-S3 antibody also inhibits pertussis toxininduced hemagglutination, suggesting that anti-B oligomer may protect mice by interfering with the B oligomer-mediated binding of pertussis toxin to the eucaryotic cell membrane. The active and passive protection data presented here suggest that elicitation of antibodies that interfere with B oligomer-mediated binding to the eucaryotic membrane, in addition to elicitation of antibodies that neutralize the ADPribosylation capacity of Si, may provide optimal protection against symptoms of disease mediated by pertussis toxin. Further analysis of the mechanisms of protection mediated by purified antigens of B. pertussis will aid in the construction of new vaccines that are safe and yet optimally effective.
